Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer

Cancer Vaccine Combo to be Tested in Triple Negative Breast Cancer
UbiVac and Bristol Myers Squibb have announced plans to collaborate on a clinical trial to test whether a combination therapy approach can boost cancer immunity in patients with advanced triple negative breast cancer. The Phase 1b trial will evaluate the safety, tolerability, and preliminary efficacy of UbiVac’s investigational product, DPV-001, in combination with Bristol Myers Squibb’s anti-OX40 (BMS-986178) and the programmed death-1 (PD-1) immune checkpoint inhibitor Opdivo (nivolumab, also by Bristol Myers Squibb). The trial will be the first to combine a cancer vaccine with a T-cell agonist (a compound that stimulates T-cells) and an anti-PD-1 immune checkpoint therapy. “We believe that cutting-edge immunotherapy combinations have the potential to induce long-lasting anticancer immunity and translate into clinical responses in patients with triple negative breast cancer,” David Page, MD, of the Providence Portland Medical Center, who will lead the trial, said in a
Subscribe or to access all post and page content.